OraSure Technologies to Present at Stephens Annual Investment Conference
OraSure Technologies (NASDAQ: OSUR) announced that CFO Ken McGrath will participate in a fireside chat at the Stephens Annual Investment Conference on November 17, 2022, at 9:00 am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OraSure Technologies (NASDAQ: OSUR) announced that CFO Ken McGrath will participate in a fireside chat at the Stephens Annual Investment Conference on November 17, 2022, at 9:00 am ET. The event will be webcast live, allowing investors and stakeholders to tune in online. Replays of the presentation will be available on the company's website for 14 days. OraSure specializes in point of care diagnostic tests and offers various health solutions through its subsidiaries, including DNA Genotek and Diversigen.
Details
News Market Reaction – OSUR
The recorded move for OSUR in the trading session of this news was -2.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BETHLEHEM, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Ken McGrath, Chief Financial Officer, will participate in a fireside chat at the Stephens Annual Investment Conference on November 17, 2022 at 9:00 am ET. The conference will be simultaneously webcast over the Internet.
Live webcasts and replays of the presentations can be accessed by going to OraSure Technologies’ web site, www.orasure.com and clicking on the Investor Info link. Replays of the webcasts will be available on OraSure Technologies’ web site for 14 days.
About OraSure Technologies
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.
Company contacts
Investor Relations Contact:
Scott Gleason
SVP of IR and Corp. Communications
484-425-0588
sgleason@orasure.com
Media Contact:
Amy Koch
Sr. Mgr. Corporate Communications
484-523-1815
media@orasure.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.